CD36	O
recognises	O
oxidized	O
low	O
density	O
lipoprotein	O
,	O
long	O
chain	O
fatty	O
acids	O
,	O
anionic	O
phospholipids	O
,	O
collagen	O
types	O
I	O
,	O
IV	O
and	O
V	O
,	O
thrombospondin	O
and	O
``	O
Plasmodium	other-disease
falciparum	other-disease
``	O
infected	O
erythrocytes	O
.	O

Ovarian	other-disease
cancer	other-disease
G-protein	O
coupled	O
receptor	O
1	O
is	O
a	O
protein	O
that	O
in	O
humans	O
is	O
encoded	O
by	O
the	O
``	O
GPR68	O
``	O
gene	O
.	O

Dr	O
.	O
Edward	O
D.	O
Miller	O
,	O
dean	O
of	O
the	O
medical	O
faculty	O
and	O
CEO	O
of	O
Johns	O
Hopkins	O
Medicine	O
,	O
said	O
that	O
Yardley	O
was	O
``	O
one	O
of	O
the	O
founding	O
fathers	O
of	O
the	O
field	O
of	O
gastrointestinal	O
pathology	O
,	O
''	O
adding	O
that	O
he	O
made	O
``	O
groundbreaking	O
observations	O
on	O
Whipple	other-disease
's	other-disease
disease	other-disease
of	O
the	O
gastrointestinal	O
tract	O
and	O
helped	O
define	O
the	O
current	O
classification	O
system	O
for	O
neoplastic	other-disease
dysplasia	other-disease
in	O
the	O
colon	other-disease
and	O
esophagus	other-disease
.	O
''	O

Pre-clinical	O
studies	O
that	O
simultaneously	O
targeted	O
mTOR	O
and	O
metabolism	O
with	O
AZD8055	O
(	O
inhibitor	O
of	O
mTORC1	O
and	O
mTORC2	O
)	O
and	O
2-DG	O
,	O
respectively	O
inhibited	O
mammary	other-disease
tumors	other-disease
from	O
forming	O
.	O

She	O
researched	O
on	O
various	O
topics	O
of	O
IVF	O
&	O
amp	O
;	O
Infertility	other-disease
during	O
her	O
specialization	O
.	O

As	O
DISC1	O
function	O
is	O
involved	O
in	O
neurogenesis	O
and	O
neuroplasticity	O
,	O
vulnerability	O
to	O
schizophrenia	other-disease
may	O
involve	O
dysfunction	O
in	O
the	O
hippocampus	O
,	O
a	O
brain	O
region	O
in	O
which	O
adult	O
neurogenesis	O
occurs	O
.	O

She	O
is	O
a	O
former	O
Chief	O
Scientific	O
Adviser	O
to	O
the	O
Alzheimer	O
's	O
Research	O
Trust	O
,	O
and	O
in	O
2012	O
was	O
appointed	O
a	O
CBE	O
for	O
her	O
contribution	O
to	O
Alzheimer	other-disease
's	O
research	O
.	O

Chronic	other-disease
kidney	other-disease
disease	other-disease
affected	O
753	O
million	O
people	O
globally	O
in	O
2016	O
:	O
417	O
million	O
females	O
and	O
336	O
million	O
males	O
.	O

Safe	O
blood	O
plays	O
a	O
life	O
saving	O
role	O
in	O
Thalassemia	other-disease
patients	O
who	O
need	O
blood	O
at	O
regular	O
intervals	O
.	O

Teva	O
and	O
Technion	O
filed	O
patent	O
applications	O
for	O
this	O
racemically	O
pure	O
compound	O
,	O
methods	O
to	O
make	O
it	O
,	O
and	O
methods	O
to	O
use	O
it	O
to	O
treat	O
Parkinsons	other-disease
and	O
other	O
disorders	O
,	O
and	O
Technion	O
eventually	O
assigned	O
its	O
rights	O
to	O
Teva	O
.	O

While	O
SNRIs	O
have	O
similar	O
efficacy	O
as	O
SSRIs	O
,	O
many	O
psychiatrists	O
prefer	O
to	O
use	O
SSRIs	O
first	O
in	O
the	O
treatment	O
of	O
Generalized	other-disease
Anxiety	other-disease
Disorder	other-disease
.	O

Vazif	O
Meylanov	O
died	O
on	O
January	O
11	O
,	O
2015	O
,	O
in	O
Makhachkala	O
after	O
suffering	O
from	O
Alzheimer	other-disease
disease	O
for	O
years	O
.	O

Measles	other-disease
first	O
arrived	O
in	O
Samoa	O
in	O
1893	O
,	O
carried	O
by	O
a	O
steamer	O
from	O
New	O
Zealand	O
.	O

Mitochondrial	other-disease
acetoacetyl-CoA	other-disease
thiolase	O
deficiency	O
,	O
known	O
earlier	O
as	O
β-ketothiolase	O
deficiency	O
,	O
is	O
an	O
inborn	O
error	O
of	O
metabolism	O
involving	O
isoleucine	O
catabolism	O
and	O
ketone	O
body	O
metabolism	O
.	O

A	O
person	O
with	O
spatial	other-disease
dysgraphia	other-disease
has	O
a	O
defect	O
in	O
the	O
understanding	O
of	O
space	O
.	O

Byers	O
'	O
debut	O
novel	O
``	O
Idiopathy	O
``	O
,	O
a	O
satire	O
based	O
on	O
the	O
spread	O
of	O
a	O
BSE	other-disease
-like	O
disease	O
,	O
received	O
a	O
Betty	O
Trask	O
Award	O
and	O
the	O
Waterstones	O
11	O
prize	O
.	O

Making	O
the	O
diagnosis	O
of	O
HCM	other-disease
often	O
involves	O
a	O
family	O
history	O
or	O
pedigree	O
,	O
an	O
electrocardiogram	O
,	O
echocardiogram	O
,	O
and	O
stress	O
testing	O
.	O

WEA	other-disease
is	O
present	O
in	O
about	O
a	O
fifth	O
of	O
patients	O
with	O
asthma	other-disease
and	O
a	O
wide	O
variety	O
of	O
conditions	O
at	O
work	O
,	O
including	O
irritant	O
chemicals	O
,	O
dusts	O
,	O
second-hand	O
smoke	O
,	O
common	O
allergens	O
that	O
may	O
be	O
present	O
at	O
work	O
,	O
as	O
well	O
as	O
other	O
“	O
exposures	O
”	O
such	O
as	O
emotional	O
stress	O
,	O
worksite	O
temperature	O
,	O
and	O
physical	O
exertion	O
can	O
exacerbate	O
asthma	other-disease
symptoms	O
in	O
these	O
patients	O
.	O

Oligohydramnios	O
can	O
be	O
caused	O
by	O
infection	O
,	O
kidney	O
dysfunction	O
or	O
malformation	O
(	O
since	O
much	O
of	O
the	O
late	O
amniotic	O
fluid	O
volume	O
is	O
urine	O
)	O
,	O
procedures	O
such	O
as	O
chorionic	O
villus	O
sampling	O
(	O
CVS	other-disease
)	O
,	O
and	O
preterm	O
premature	O
rupture	O
of	O
membranes	O
(	O
PPROM	other-disease
)	O
.	O

Purpura	other-disease
fulminans	other-disease
secondary	O
to	O
severe	O
infection	O
is	O
self-limiting	O
.	O

Urinary	other-disease
tract	other-disease
infection	other-disease
is	O
the	O
most	O
common	O
complication	O
of	O
intermittent	other-disease
catheterization	other-disease
.	O

Migraine	other-disease
surgery	O
is	O
usually	O
reserved	O
for	O
migraine	other-disease
patients	O
who	O
fail	O
more	O
conservative	O
therapy	O
or	O
who	O
can	O
not	O
tolerate	O
the	O
side	O
effects	O
of	O
drugs	O
used	O
to	O
treat	O
their	O
migraines	other-disease
.	O

He	O
felt	O
he	O
lacked	O
expertise	O
in	O
rheumatic	other-disease
diseases	other-disease
and	O
determined	O
to	O
teach	O
himself	O
.	O

Schwartz	O
is	O
credited	O
with	O
the	O
clinical	O
description	O
of	O
new	O
subtypes	O
of	O
Kaposi	other-disease
's	other-disease
sarcoma	other-disease
:	O
telangiectatic	other-disease
Kaposi	other-disease
's	other-disease
sarcoma	other-disease
,	O
keloidal	other-disease
Kaposi	other-disease
's	other-disease
sarcoma	other-disease
and	O
ecchymotic	other-disease
Kaposi	other-disease
’	other-disease
s	other-disease
sarcoma	other-disease
.	O

Conduct	other-disease
disorder	other-disease
is	O
associated	O
with	O
both	O
structural	O
abnormalities	O
,	O
and	O
functional	O
abnormalities	O
during	O
affective	O
tasks	O
.	O

Watsu	O
has	O
been	O
proposed	O
as	O
a	O
therapy	O
for	O
fibromyalgia	other-disease
syndrome	other-disease
,	O
and	O
for	O
rehabilitating	O
patients	O
after	O
a	O
stroke	other-disease
.	O

Acute	O
HIV	other-disease
infection	O
can	O
mimic	O
signs	O
similar	O
to	O
those	O
of	O
infectious	O
mononucleosis	O
,	O
and	O
tests	O
should	O
be	O
performed	O
for	O
pregnant	O
women	O
for	O
the	O
same	O
reason	O
as	O
toxoplasmosis	other-disease
.	O

Arthur	O
's	O
mother-in-law	O
,	O
Janet	O
Brain	O
's	O
mother	O
,	O
was	O
Stella	O
Langdon	O
Down	O
,	O
the	O
granddaughter	O
of	O
John	O
Langdon	O
Down	O
who	O
gave	O
the	O
first	O
systematic	O
description	O
of	O
Down	other-disease
syndrome	other-disease
in	O
1867	O
and	O
after	O
whom	O
the	O
syndrome	O
is	O
named	O
.	O

Mumps	other-disease
meningitis	other-disease
typically	O
resolves	O
within	O
3–10	O
days	O
without	O
long-term	O
complications	O
.	O

He	O
also	O
set	O
up	O
Scotland	O
's	O
endoscopic	O
surveillance	O
service	O
for	O
Barrett	other-disease
's	other-disease
esophagus	other-disease
(	O
ESBE	O
)	O
between	O
1988–1991	O
at	O
Ninewells	O
Hospital	O
of	O
Dundee	O

Patients	O
with	O
lcSSc	other-disease
commonly	O
induce	O
pulmonary	O
artery	O
hypertension	O
which	O
may	O
result	O
in	O
cor	O
pulmonale	O
(	O
heart	O
failure	O
due	O
to	O
increased	O
pulmonary	O
artery	O
pressure	O
)	O
.	O

In	O
breast	other-disease
cancer	other-disease
brachyury	O
expression	O
is	O
associated	O
with	O
recurrence	O
,	O
metastasis	O
and	O
reduced	O
survival	O
.	O

The	O
prevalence	O
of	O
HIV	other-disease
/	O
AIDS	other-disease
in	O
the	O
Dominican	O
Republic	O
in	O
2011	O
stood	O
at	O
approximately	O
0.7	O
%	O
,	O
which	O
is	O
relatively	O
low	O
by	O
Caribbean	O
standards	O
,	O
with	O
an	O
estimated	O
62,000	O
HIV	other-disease
/	O
AIDS	other-disease
-positive	O
Dominicans	O
.	O

It	O
follows	O
then	O
that	O
,	O
on	O
the	O
basis	O
of	O
the	O
fact	O
that	O
ventricular	other-disease
fibrillation	other-disease
itself	O
is	O
common	O
,	O
idiopathic	other-disease
ventricular	other-disease
fibrillation	other-disease
accounts	O
for	O
an	O
appreciable	O
mortality	O
.	O

Infectious	O
causes	O
include	O
syphilis	other-disease
(	O
commonest	O
)	O
,	O
followed	O
by	O
other	O
bacterial	O
infections	O
(	O
TB	other-disease
,	O
Leprosy	other-disease
and	O
Lyme	other-disease
disease	O
)	O
and	O
parasitic	O
infections	O
(	O
Acanthamoeba	other-disease
,	O
Onchocerciasis	other-disease
or	O
river	other-disease
blindness	other-disease
,	O
Leishmaniasis	other-disease
,	O
Trypanosoma	other-disease
cruzi	other-disease
or	O
``	O
Chagas	other-disease
disease	other-disease
``	O
,	O
Trypanosoma	other-disease
brucei	other-disease
or	O
``	O
African	other-disease
sleeping	other-disease
sickness	other-disease
``	O
and	O
microsporidia	other-disease
)	O

Panhypopituitarism	O
and	O
hypothyroidism	other-disease
have	O
each	O
been	O
diagnosed	O
in	O
a	O
handful	O
of	O
individuals	O
.	O

Professor	O
Akiskal	O
rose	O
to	O
prominence	O
with	O
his	O
integrative	O
theory	O
of	O
depression	other-disease
.	O

There	O
are	O
several	O
preventive	O
foot	O
hygiene	O
measures	O
that	O
can	O
prevent	O
athlete	other-disease
's	other-disease
foot	other-disease
and	O
reduce	O
recurrence	O
.	O

The	O
city	O
wall	O
in	O
the	O
film	O
is	O
an	O
important	O
motif	O
,	O
as	O
its	O
dilapidated	O
state	O
reflects	O
not	O
only	O
the	O
physical	O
destruction	O
of	O
the	O
war	O
,	O
but	O
also	O
the	O
general	O
post-war	O
depression	O
of	O
the	O
people	O
;	O
the	O
latter	O
is	O
personified	O
by	O
the	O
male	O
protagonist	O
,	O
Dai	O
Liyan	O
,	O
who	O
suffers	O
from	O
a	O
psychosomatic	other-disease
illness	other-disease
as	O
he	O
struggles	O
to	O
cope	O
with	O
the	O
destruction	O
and	O
decline	O
of	O
his	O
estate	O
following	O
the	O
War	O
.	O

Borna	other-disease
disease	O
viruses	other-disease
1	other-disease
and	other-disease
2	other-disease
are	O
neurotropic	O
viruses	O
and	O
members	O
of	O
the	O
``	O
Bornaviridae	other-disease
``	O
family	O
within	O
the	O
``	O
Mononegavirales	other-disease
``	O
order	O
.	O

Attention	other-disease
deficit	other-disease
hyperactivity	other-disease
disorder	other-disease
(	O
ADHD	other-disease
)	O
is	O
known	O
to	O
be	O
highly	O
comorbid	O
with	O
conduct	O
disorder	O
(	O
a	O
theorized	O
precursor	O
to	O
ASPD	other-disease
)	O
,	O
and	O
may	O
also	O
co-occur	O
with	O
psychopathic	O
tendencies	O
.	O

The	O
vine	O
ripens	O
late	O
and	O
is	O
susceptible	O
to	O
many	O
grape	O
diseases	O
including	O
oidium	other-disease
.	O

Insomnia	other-disease
,	O
chronic	other-disease
respiratory	other-disease
infections	other-disease
,	O
general	other-disease
pain	other-disease
and	O
discomfort	other-disease
,	O
impotence	other-disease
,	other-disease
flatulence	other-disease
,	O
and	O
bowel	other-disease
complaints	other-disease
were	O
all	O
reported	O
.	O

While	O
collecting	O
material	O
for	O
this	O
work	O
Plant	O
contracted	O
malaria	other-disease
in	O
Maputaland	O
,	O
dying	O
at	O
Lake	O
St.	O
Lucia	O
in	O
1858	O
.	O

Agents	O
with	O
an	O
effect	O
on	O
hepatic	O
cytochrome	O
P450	O
pathways	O
or	O
conjugation	O
can	O
alter	O
the	O
rate	O
of	O
diazepam	other-disease
metabolism	O
.	O

They	O
involve	O
a	O
progression	O
of	O
the	O
location	O
of	O
the	O
seizure	other-disease
in	O
the	O
brain	O
,	O
which	O
leads	O
to	O
a	O
``	O
march	O
''	O
of	O
the	O
motor	O
presentation	O
of	O
symptoms	O
.	O

BTG	O
subsequently	O
won	O
approvals	O
for	O
orphan	O
drug	O
status	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
for	O
treating	O
alcoholic	O
hepatitis	O
,	O
Turner	other-disease
syndrome	O
,	O
and	O
HIV	other-disease
-induced	O
weight	O
loss	O
.	O

Eyelid	other-disease
dermatitis	other-disease
is	O
commonly	O
related	O
to	O
atopic	other-disease
dermatitis	other-disease
or	O
allergic	other-disease
contact	other-disease
dermatitis	other-disease
.	O

Sudden	O
explosive	O
noises	O
typical	O
of	O
high-performance	O
car	O
exhausts	O
and	O
car	O
alarms	O
are	O
types	O
of	O
noise	O
pollution	O
that	O
can	O
affect	O
people	O
with	O
ASD	other-disease
.	O

However	O
due	O
to	O
the	O
COVID-19	other-disease
Pandemic	O
the	O
baggage	O
car	O
has	O
been	O
temporarily	O
removed	O
from	O
the	O
consist	O
.	O

Njølstad	other-disease
syndrom	other-disease
e	O
is	O
a	O
syndrome	O
characterized	O
by	O
non-immune	other-disease
hydrops	other-disease
fetalis	other-disease
(	O
NIHF	other-disease
)	O
,	O
congenital	other-disease
pulmonary	other-disease
lymphangiectasia	other-disease
(	O
CPL	other-disease
)	O
.	O

Penile	other-disease
dysmorphophobi	other-disease
a	O
is	O
related	O
to	O
body	other-disease
dysmorphic	other-disease
disorder	other-disease
(	O
BDD	other-disease
)	O
,	O
defined	O
by	O
the	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders-Fourth	O
Edition	O
(	O
Text	O
Revision	O
)	O
(	O
DSM-IV-TR	O
)	O
as	O
a	O
condition	O
marked	O
by	O
excessive	O
preoccupation	O
with	O
an	O
imaginary	O
or	O
minor	O
defect	O
in	O
a	O
facial	O
feature	O
or	O
localized	O
part	O
of	O
the	O
body	O
.	O

Like	O
dopamine	O
,	O
norepinephrine	O
,	O
and	O
serotonin	O
,	O
the	O
trace	O
amines	O
have	O
been	O
implicated	O
in	O
a	O
vast	O
array	O
of	O
human	O
disorders	O
of	O
affect	O
and	O
cognition	O
,	O
such	O
as	O
ADHD	other-disease
,	O
depression	other-disease
and	O
schizophrenia	O
,	O
among	O
others	O
.	O

Social-emotional	other-disease
agnosia	other-disease
,	O
also	O
known	O
as	O
emotional	other-disease
agnosia	other-disease
or	O
expressive	other-disease
agnosia	other-disease
,	O
is	O
the	O
inability	O
to	O
perceive	O
facial	O
expressions	O
,	O
body	O
language	O
,	O
and	O
voice	O
intonation	O
.	O

At	O
the	O
beginning	O
of	O
the	O
AIDS	other-disease
epidemic	O
in	O
the	O
early	O
1980s	O
,	O
cyclosporiasis	other-disease
was	O
identified	O
as	O
one	O
of	O
the	O
most	O
important	O
opportunistic	O
infections	O
among	O
AIDS	other-disease
patients	O
.	O

Likewise	O
,	O
mutations	O
in	O
PRC2	O
genes	O
were	O
related	O
to	O
hematological	O
conditions	O
such	O
as	O
acute	other-disease
lymphoblastic	other-disease
leukemia	other-disease
(	O
ALL	other-disease
)	O
,	O
which	O
is	O
a	O
form	O
of	O
leukemia	other-disease
.	O

Mutations	O
of	O
this	O
gene	O
are	O
commonly	O
found	O
in	O
a	O
variety	O
of	O
cancers	O
:	O
in	O
primary	other-disease
hepatocellular	other-disease
carcinoma	other-disease
,	O
colorectal	other-disease
cancer	other-disease
,	O
ovarian	other-disease
carcinoma	other-disease
,	O
breast	other-disease
cancer	other-disease
,	O
lung	other-disease
cancer	other-disease
and	O
glioblastoma	other-disease
.	O

The	O
hospital	O
is	O
still	O
serving	O
the	O
public	O
and	O
came	O
into	O
the	O
international	O
spotlight	O
when	O
it	O
was	O
designated	O
as	O
the	O
sole	O
treatment	O
centre	O
for	O
the	O
SARS	other-disease
epidemic	O
which	O
struck	O
Singapore	O
in	O
2003	O
.	O

Neuro-imaging	O
should	O
also	O
be	O
used	O
to	O
look	O
for	O
a	O
stroke	O
,	O
tumor	O
,	O
infection	O
,	O
or	O
another	O
pathology	O
in	O
the	O
setting	O
of	O
conduction	O
aphasia	other-disease
.	O

PAH	O
deficiency	O
causes	O
a	O
spectrum	O
of	O
disorders	O
,	O
including	O
classic	O
phenylketonuria	other-disease
(	O
PKU	other-disease
)	O
and	O
mild	other-disease
hyperphenylalaninemia	other-disease
(	O
also	O
known	O
as	O
``	O
hyperphe	other-disease
``	O
or	O
``	O
mild	other-disease
HPA	other-disease
``	O
)	O
,	O
a	O
less	O
severe	O
accumulation	O
of	O
phenylalanine	O
.	O

Long-chain	O
L-3-hydroxyacyl-coenzyme	O
A	O
dehydrogenase	O
deficiency	O
is	O
associated	O
with	O
some	O
pregnancy-specific	O
disorders	O
,	O
including	O
preeclampsia	other-disease
,	O
HELLP	other-disease
syndrome	O
(	O
hemolysis	other-disease
,	O
elevated	O
liver	O
enzymes	O
,	O
low	O
platelets	O
)	O
,	O
hyperemesis	other-disease
gravidarum	other-disease
,	O
acute	other-disease
fatty	other-disease
liver	other-disease
of	other-disease
pregnancy	other-disease
,	O
and	O
maternal	other-disease
floor	other-disease
infarct	other-disease
of	other-disease
the	other-disease
placenta	other-disease
.	O

The	O
World	O
Health	O
Organization	O
classifies	O
Buruli	other-disease
ulcer	other-disease
into	O
three	O
categories	O
depending	O
on	O
the	O
severity	O
of	O
its	O
symptoms	O
.	O

Risk	O
factors	O
for	O
OSA	other-disease
include	O
being	O
overweight	O
,	O
a	O
family	O
history	O
of	O
the	O
condition	O
,	O
allergies	O
,	O
a	O
small	O
breathing	O
airway	O
,	O
and	O
enlarged	O
tonsils	O
.	O

Hypokalemia	other-disease
is	O
often	O
asymptomatic	O
,	O
and	O
symptoms	O
may	O
not	O
appear	O
until	O
potassium	O
concentration	O
is	O
&	O
lt	O
;	O
2.5	O
mEq/L	O
.	O

Thus	O
,	O
for	O
a	O
brief	O
time	O
malaria	other-disease
was	O
used	O
as	O
treatment	O
for	O
tertiary	other-disease
syphilis	other-disease
because	O
it	O
produced	O
prolonged	O
and	O
high	other-disease
fevers	other-disease
(	O
a	O
form	O
of	O
pyrotherapy	O
)	O
.	O

Acquired	other-disease
and	other-disease
secondary	other-disease
strabismus	other-disease
develop	O
later	O
.	O

These	O
neurodegenerative	O
diseases	O
are	O
commonly	O
called	O
``	O
prion	other-disease
diseases	other-disease
``	O
.	O

Ectrodactyly	other-disease
can	O
be	O
caused	O
by	O
various	O
changes	O
to	O
7q	O
.	O

AIDS	other-disease
is	O
defined	O
as	O
the	O
clinical	O
stage	O
IV	O
of	O
the	O
HIV	O
infection	O
.	O

Dati	O
survived	O
two	O
bouts	O
of	O
Bubonic	other-disease
plague	other-disease
that	O
struck	O
his	O
family	O
,	O
and	O
would	O
go	O
on	O
to	O
outlive	O
three	O
of	O
his	O
wives	O
and	O
19	O
of	O
his	O
children	O
.	O

Tuberculin	O
reaction	O
or	O
Type	other-disease
1	other-disease
diabetes	other-disease
belong	O
to	O
this	O
category	O
of	O
autoimmunity	O
.	O

It	O
should	O
not	O
be	O
confused	O
with	O
periorbital	other-disease
cellulitis	other-disease
,	O
which	O
refers	O
to	O
cellulitis	other-disease
anterior	other-disease
to	other-disease
the	other-disease
septum	other-disease
.	O

Renal	other-disease
insufficiency	other-disease
is	O
always	O
progressive	O
with	O
a	O
very	O
poor	O
prognosis	O
,	O
with	O
survival	O
at	O
1	O
and	O
2	O
months	O
of	O
20	O
and	O
10	O
%	O
respectively	O
.	O

X-linked	other-disease
thrombocytopenia	other-disease
is	O
typically	O
diagnosed	O
in	O
infancy	O
.	O

The	O
Treatment	O
Action	O
Campaign	O
(	O
TAC	O
)	O
is	O
a	O
South	O
African	O
HIV	other-disease
/	O
AIDS	other-disease
activist	O
organisation	O
which	O
was	O
co-founded	O
by	O
the	O
HIV	other-disease
-positive	O
activist	O
Zackie	O
Achmat	O
in	O
1998	O
.	O

After	O
a	O
sleepover	O
at	O
Milhouse	O
's	O
,	O
Milhouse	O
,	O
Nelson	O
,	O
and	O
Bart	O
find	O
themselves	O
in	O
a	O
cell	O
,	O
trapped	O
by	O
Lisa	O
,	O
suffering	O
from	O
dissociative	other-disease
identity	other-disease
disorder	other-disease
(	O
similar	O
to	O
James	O
McAvoy	O
's	O
character	O
from	O
``	O
Split	O
``	O
)	O
,	O
then	O
closes	O
them	O
in	O
again	O
after	O
they	O
do	O
not	O
ask	O
for	O
an	O
encore	O
on	O
her	O
performance	O
.	O

About	O
half	O
of	O
patients	O
have	O
associated	O
dystonia	other-disease
,	O
including	O
cervical	other-disease
dystonia	other-disease
,	O
writer	other-disease
's	other-disease
cramp	other-disease
,	O
spasmodic	other-disease
dysphonia	other-disease
,	O
and	O
cranial	other-disease
dystonia	other-disease
,	O
and	O
20	O
%	O
of	O
the	O
patients	O
had	O
associated	O
parkinsonism	other-disease
.	O

Pneumothorax	O
is	O
a	O
well-known	O
complication	O
of	O
PCP	other-disease
.	O

One	O
early	O
description	O
of	O
HACE	other-disease
may	O
have	O
been	O
published	O
in	O
1969	O
after	O
a	O
group	O
of	O
Indian	O
soldiers	O
made	O
a	O
rapid	O
ascent	O
to	O
almost	O
.	O

Biotron	O
has	O
identified	O
a	O
new	O
class	O
of	O
viral	O
proteins	O
as	O
targets	O
for	O
potential	O
intervention	O
,	O
and	O
is	O
developing	O
novel	O
small	O
molecule	O
therapeutics	O
that	O
target	O
these	O
proteins	O
,	O
specifically	O
the	O
p7	O
protein	O
of	O
Hepatitis	other-disease
C	other-disease
and	O
Vpu	O
protein	O
of	O
HIV	O
.	O

However	O
,	O
the	O
promotion	O
of	O
safe	O
sex	O
and	O
contraception	O
throughout	O
the	O
HIV/AIDS	other-disease
epidemic	other-disease
and	O
the	O
promotion	O
of	O
positive	O
LGBT	O
themes	O
has	O
increased	O
awareness	O
and	O
normalized	O
the	O
concept	O
of	O
sexual	O
diversity	O
within	O
Peru	O
.	O

Additionally	O
,	O
reduction	O
in	O
GFAP	O
expression	O
has	O
also	O
been	O
reported	O
in	O
Wernicke	other-disease
's	other-disease
encephalopathy	other-disease
.	O

The	O
symptoms	O
of	O
a	O
Staph	O
Infection	O
include	O
a	O
collection	other-disease
of	other-disease
pus	other-disease
,	O
such	O
as	O
a	O
boil	other-disease
or	O
furuncle	other-disease
,	O
or	O
a	O
bscess	other-disease
.	O

Overdose	O
may	O
result	O
in	O
central	O
nervous	O
system	O
toxicity	O
,	O
cardiovascular	other-disease
toxicity	other-disease
,	O
tendon/articular	other-disease
toxicity	other-disease
,	O
and	O
hepatic	other-disease
toxicity	other-disease
as	O
well	O
as	O
kidney	other-disease
failure	other-disease
and	O
seizure	other-disease
.	O

Along	O
with	O
Ray	O
Illingworth	O
,	O
Geoff	O
Boycott	O
and	O
John	O
Edrich	O
,	O
John	O
Snow	O
declined	O
to	O
tour	O
India	O
in	O
1972–73	O
,	O
wanting	O
to	O
rest	O
his	O
back	O
for	O
the	O
summer	O
and	O
concerned	O
about	O
the	O
dysentery	other-disease
he	O
had	O
caught	O
in	O
Pakistan	O
in	O
1968–69	O
.	O

Autoimmune	other-disease
polyendocrine	other-disease
syndrome	other-disease
type	other-disease
1	other-disease
is	O
inherited	O
in	O
an	O
autosomal	O
recessive	O
manner	O
.	O

The	O
vaccine	O
contains	O
living	O
``	O
Mycobacterium	O
bovis	O
``	O
BCG	O
,	O
and	O
in	O
BCG	other-disease
disease	other-disease
,	O
the	O
bacterium	O
causes	O
a	O
disease	O
in	O
persons	O
vaccinated	O
.	O

More	O
proximal	O
portions	O
of	O
the	O
artery	O
may	O
cause	O
spastic	other-disease
paraparesis	other-disease
and	O
sensory	other-disease
loss	other-disease
contralateral	other-disease
to	O
the	O
lesioned	O
side	O
.	O

On	O
the	O
evening	O
of	O
November	O
2	O
,	O
2008	O
,	O
in	O
North	O
Las	O
Vegas	O
,	O
Nevada	O
,	O
Tolbert	O
suffered	O
a	O
heart	other-disease
attack	other-disease
while	O
driving	O
alone	O
near	O
the	O
Obama	O
campaign	O
offices	O
.	O

In	O
2002	O
,	O
763,917	O
new	O
cases	O
were	O
detected	O
worldwide	O
,	O
and	O
in	O
that	O
year	O
the	O
WHO	O
listed	O
India	O
,	O
Brazil	O
,	O
Madagascar	O
,	O
Mozambique	O
,	O
Tanzania	O
and	O
Nepal	O
as	O
having	O
90	O
%	O
of	O
Hansen	other-disease
's	other-disease
disease	other-disease
cases	O
.	O

Obstructive	O
(	O
OSA	other-disease
)	O
is	O
the	O
most	O
common	O
form	O
.	O

Since	O
the	O
acetylation	O
of	O
STAT3	O
is	O
important	O
for	O
its	O
oncogenic	O
activity	O
and	O
the	O
fact	O
that	O
the	O
level	O
of	O
acetylated	O
STAT3	O
is	O
high	O
in	O
cancer	other-disease
cells	O
,	O
it	O
is	O
implied	O
that	O
targeting	O
acetylated	O
STAT3	O
for	O
chemoprevention	O
and	O
chemotherapy	O
is	O
a	O
promising	O
strategy	O
.	O

In	O
Bloom	other-disease
syndrome	other-disease
,	O
those	O
afflicted	O
most	O
often	O
die	O
of	O
cancer	other-disease
.	O

In	O
Peru	O
today	O
,	O
HIV	other-disease
infections	other-disease
are	O
concentrated	O
among	O
many	O
low-income	O
Peruvian	O
men	O
who	O
have	O
engaged	O
in	O
same-sex	O
sexual	O
contact	O
.	O

During	O
the	O
Great	other-disease
Plague	other-disease
of	other-disease
London	other-disease
in	O
1665	O
,	O
people	O
boarded	O
coaches	O
at	O
Whitehall	O
,	O
then	O
at	O
the	O
edge	O
of	O
urban	O
London	O
,	O
in	O
an	O
attempt	O
to	O
escape	O
.	O

Up	O
to	O
9	O
%	O
of	O
VLBWI	other-disease
with	O
birth	O
weights	O
of	O
&	O
lt	O
;	O
1,000	O
g	O
develop	O
these	O
fungus	O
infections	O
leading	O
to	O
sepsis	other-disease
or	O
meningitis	other-disease
.	O

Diseases	O
categorized	O
as	O
primary	O
autonomic	O
failure	O
usually	O
include	O
pure	other-disease
autonomic	other-disease
failure	other-disease
and	O
multiple	other-disease
system	other-disease
atrophy	other-disease
.	O

Fungal	other-disease
sinusitis	other-disease
is	O
the	O
inflammation	O
of	O
the	O
lining	O
mucosa	O
of	O
the	O
paranasal	O
sinuses	O
due	O
to	O
fungal	O
infection	O
.	O

There	O
he	O
lived	O
the	O
simple	O
life	O
of	O
a	O
holy	O
man	O
until	O
in	O
May	O
1968	O
he	O
died	O
,	O
aged	O
59	O
,	O
of	O
bleeding	O
from	O
a	O
chronic	other-disease
stomach	other-disease
ulcer	other-disease
.	O

In	O
2020	O
,	O
increased	O
attacks	O
,	O
both	O
physically	O
and	O
verbally	O
,	O
have	O
occurred	O
against	O
Asian-Americans	O
as	O
a	O
result	O
of	O
COVID-19	other-disease
paranoia	O
and	O
racism	O
.	O

In	O
many	O
cases	O
,	O
however	O
,	O
especially	O
in	O
people	O
with	O
alcoholic	other-disease
intoxication	other-disease
,	O
hypoglycemia	other-disease
appears	O
to	O
be	O
a	O
more	O
common	O
cause	O
.	O

Two	O
disorders	O
,	O
achondroplasia	other-disease
and	O
growth	O
hormone	O
deficiency	O
,	O
are	O
responsible	O
for	O
the	O
majority	O
of	O
human	O
dwarfism	other-disease
cases	O
.	O

Gigantism	other-disease
and	O
flightlessness	O
are	O
almost	O
exclusively	O
correlated	O
.	O

Sometimes	O
a	O
CSF	other-disease
leak	other-disease
will	O
heal	O
on	O
its	O
own	O
.	O

With	O
a	O
COPD	other-disease
prevalence	O
of	O
more	O
than	O
12	O
million	O
(	O
possibly	O
24	O
million	O
including	O
undiagnosed	O
ones	O
)	O
in	O
the	O
United	O
States	O
,	O
there	O
are	O
at	O
least	O
30	O
million	O
incidences	O
of	O
AECB	other-disease
annually	O
in	O
the	O
US	O
.	O

Skin	O
lesions	O
are	O
edematous	other-disease
,	O
urticarialike	other-disease
annular	other-disease
papules	other-disease
and	O
plaques	other-disease
.	O

giardiasis	other-disease
,	O
toxoplasmosis	other-disease
,	O
cryptosporidiosis	other-disease
,	O
trichomoniasis	other-disease
,	O
Chagas	other-disease
disease	other-disease
,	O
leishmaniasis	other-disease
,	O
African	other-disease
trypanosomiasis	other-disease
(	O
sleeping	other-disease
sickness	other-disease
)	O
,	O
``	other-disease
Acanthamoeba	other-disease
''	other-disease
keratitis	other-disease
,	O
and	O
primary	other-disease
amoebic	other-disease
meningoencephalitis	other-disease
(	O
naegleriasis	other-disease
)	O
.	O

Graphic	O
designer	O
Baxter	O
Orr	O
did	O
his	O
own	O
take	O
on	O
Fairey	O
's	O
work	O
:	O
a	O
piece	O
called	O
Protect	O
,	O
with	O
the	O
iconic	O
Obey	O
Giant	O
face	O
covered	O
by	O
a	O
SARS	other-disease
(	O
respiratory	O
)	O
mask	O
.	O

The	O
types	O
of	O
Emery–Dreifuss	other-disease
muscular	other-disease
dystrophy	other-disease
are	O
distinguished	O
by	O
their	O
pattern	O
of	O
inheritance	O
:	O
X-linked	O
,	O
autosomal	O
dominant	O
,	O
and	O
autosomal	O
recessive	O
.	O

Other	O
possibilities	O
that	O
have	O
been	O
advanced	O
have	O
included	O
cystic	other-disease
fibrosis	other-disease
,	O
cirrhosis	other-disease
,	O
and	O
alpha	other-disease
1-antitrypsin	other-disease
deficiency	other-disease
.	O

Complications	O
of	O
lead	O
poisoning	O
include	O
anemia	other-disease
,	O
growth	other-disease
retardation	other-disease
,	O
low	O
IQ	O
,	O
convulsions	other-disease
,	O
and	O
in	O
severe	O
cases	O
,	O
death	O
.	O

Ciprofloxacin	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
gonorrhea	other-disease
in	O
many	O
countries	O
,	O
but	O
this	O
recommendation	O
is	O
widely	O
regarded	O
as	O
obsolete	O
due	O
to	O
resistance	O
development	O
.	O

Jacksonian	other-disease
march	other-disease
or	O
Jacksonian	other-disease
seizure	other-disease
is	O
a	O
phenomenon	O
where	O
a	O
simple	O
partial	O
seizure	O
spreads	O
from	O
the	O
distal	O
part	O
of	O
the	O
limb	O
toward	O
the	O
ipsilateral	O
face	O
(	O
on	O
same	O
side	O
of	O
body	O
)	O
.	O

Dengue	other-disease
fever	other-disease
has	O
become	O
endemic	O
to	O
the	O
republic	O
,	O
cases	O
of	O
malaria	other-disease
,	O
and	O
Zika	other-disease
virus	other-disease
.	O

STAT5	O
is	O
important	O
for	O
regulatory	O
T	O
cell	O
(	O
Treg	O
)	O
differentiation	O
and	O
function	O
,	O
which	O
may	O
explain	O
why	O
many	O
STAT	other-disease
GOF	other-disease
patients	O
have	O
low	O
Tregs	O
.	O

This	O
can	O
cause	O
individuals	O
with	O
ASD	other-disease
to	O
avoid	O
environments	O
with	O
noise	O
pollution	O
,	O
which	O
in	O
turn	O
can	O
result	O
in	O
isolation	O
and	O
negatively	O
affect	O
their	O
quality	O
of	O
life	O
.	O

A	O
small	O
percentage	O
of	O
cases	O
occur	O
when	O
only	O
some	O
of	O
the	O
body	O
's	O
cells	O
have	O
an	O
extra	O
copy	O
;	O
such	O
cases	O
are	O
called	O
mosaic	other-disease
Patau	other-disease
.	O

These	O
masculine	O
characteristics	O
include	O
:	O
clitoral	other-disease
hypertrophy	other-disease
,	O
androgenic	other-disease
alopecia	other-disease
,	O
growth	O
of	O
body	O
hair	O
and	O
deepening	O
of	O
the	O
vocal	O
cords	O
.	O

Kenneth	O
Levin	O
,	O
a	O
Harvard	O
psychiatrist	O
,	O
says	O
that	O
Jewish	O
self-hatred	O
has	O
two	O
causes	O
:	O
Stockholm	other-disease
syndrome	other-disease
,	O
where	O
``	O
population	O
segments	O
under	O
chronic	O
siege	O
commonly	O
embrace	O
the	O
indictments	O
of	O
their	O
besiegers	O
however	O
bigoted	O
and	O
outrageous	O
''	O
,	O
as	O
well	O
as	O
``	O
the	O
psychodynamics	O
of	O
abused	O
children	O
,	O
who	O
almost	O
invariably	O
blame	O
themselves	O
for	O
their	O
predicament	O
,	O
ascribe	O
it	O
to	O
their	O
being	O
``	O
bad	O
,	O
''	O
and	O
nurture	O
fantasies	O
that	O
by	O
becoming	O
``	O
good	O
''	O
they	O
can	O
mollify	O
their	O
abusers	O
and	O
end	O
their	O
torment	O
.	O
''	O

The	O
Leicestershire	O
Perinatal	O
Mortality	O
Survey	O
for	O
the	O
years	O
1976	O
to	O
1982	O
found	O
high	O
incidences	O
of	O
Meckel	other-disease
syndrome	other-disease
in	O
Gujarati	O
immigrants	O
.	O

The	O
duration	O
of	O
kidney	other-disease
ischemia	other-disease
does	O
not	O
affect	O
kidney	O
function	O
either	O
in	O
the	O
short	O
term	O
or	O
long	O
term	O
.	O

GM3	O
has	O
been	O
found	O
to	O
reduce	O
the	O
motility	O
of	O
ovarian	other-disease
cancer	other-disease
cells	O
,	O
colorectal	other-disease
cancer	other-disease
cells	O
,	O
and	O
gastric	other-disease
cancer	other-disease
cells	O
.	O

Growth	other-disease
hormone	other-disease
deficiency	other-disease
has	O
been	O
reported	O
in	O
several	O
individuals	O
with	O
18p-	O
,	O
though	O
not	O
at	O
the	O
same	O
frequency	O
as	O
in	O
the	O
distal	O
18q-	O
population	O
.	O

Deletion	O
of	O
the	O
GABRB3	O
gene	O
results	O
in	O
Angelman	other-disease
syndrome	other-disease
in	O
humans	O
,	O
depending	O
on	O
the	O
parental	O
origin	O
of	O
the	O
deletion	O
.	O

Due	O
to	O
its	O
subtle	O
presentation	O
,	O
MAIS	other-disease
is	O
not	O
typically	O
investigated	O
except	O
in	O
the	O
case	O
of	O
male	O
infertility	O
,	O
thus	O
its	O
true	O
prevalence	O
is	O
unknown	O
.	O

People	O
suffering	O
from	O
Bothnia	other-disease
dystrophy	other-disease
have	O
a	O
homozygous	O
C	O
to	O
T	O
base	O
pair	O
substitution	O
in	O
exon	O
7	O
of	O
the	O
RLBP1	O
gene	O
.	O

Some	O
symptoms	O
of	O
BFLS	other-disease
are	O
discernible	O
at	O
birth	O
,	O
but	O
they	O
develop	O
over	O
time	O
.	O

Hearing	O
impairment	O
may	O
also	O
be	O
the	O
result	O
of	O
certain	O
diseases	O
such	O
as	O
CMV	other-disease
or	O
Ménière	other-disease
's	other-disease
disease	other-disease
and	O
these	O
can	O
be	O
diagnosed	O
from	O
the	O
shape	O
of	O
the	O
audiogram	O
.	O

PKHD1	other-disease
is	O
involved	O
.	O

Some	O
examples	O
of	O
behavioral	O
disorders	O
include	O
anxiety	other-disease
,	O
alcohol	other-disease
dependence	other-disease
,	O
and	O
drug	O
use	O
.	O

Beginning	O
in	O
Colombia	O
,	O
smallpox	other-disease
spread	O
rapidly	O
before	O
the	O
Spanish	O
invaders	O
first	O
arrived	O
in	O
the	O
empire	O
.	O

Other	O
conditions	O
associated	O
with	O
this	O
condition	O
include	O
acanthosis	other-disease
nigricans	other-disease
,	O
fatty	other-disease
liver	other-disease
,	O
hypertriglyceridemia	other-disease
and	O
polycystic	other-disease
ovary	other-disease
syndrome	other-disease
in	O
women	O
.	O

It	O
is	O
sometimes	O
used	O
off-label	O
for	O
the	O
treatment	O
of	O
fibromyalgia	other-disease
.	O

Ian	O
Frazer	O
,	O
one	O
of	O
the	O
developers	O
of	O
the	O
Gardasil	other-disease
cervical	other-disease
cancer	other-disease
vaccine	O
,	O
is	O
the	O
scientific	O
advisor	O
to	O
ACCF	O
.	O

Furthermore	O
,	O
nitric	O
oxide	O
may	O
cause	O
kidney	O
damage	O
and	O
is	O
not	O
recommended	O
as	O
therapy	O
for	O
ARDS	other-disease
regardless	O
of	O
severity	O
.	O

Sexual	other-disease
dysfunction	other-disease
often	O
accompanies	O
anxiety	other-disease
disorders	other-disease
,	O
although	O
it	O
is	O
difficult	O
to	O
determine	O
whether	O
anxiety	O
causes	O
the	O
sexual	other-disease
dysfunction	other-disease
or	O
whether	O
they	O
arise	O
from	O
a	O
common	O
cause	O
.	O

Gangrene	other-disease
is	O
caused	O
by	O
a	O
critically	O
insufficient	O
blood	O
supply	O
(	O
e.g.	O
,	O
peripheral	other-disease
vascular	other-disease
disease	other-disease
)	O
or	O
infection	O
.	O

Antithrombin	O
deficiency	O
is	O
present	O
in	O
0.2	O
%	O
of	O
the	O
general	O
population	O
and	O
0.5–7.5	O
%	O
of	O
people	O
with	O
venous	other-disease
thrombosis	other-disease
.	O

About	O
30	O
percent	O
of	O
men	O
with	O
Peyronie	other-disease
's	other-disease
disease	other-disease
develop	O
fibrosis	O
in	O
other	O
elastic	O
tissues	O
of	O
the	O
body	O
,	O
such	O
as	O
on	O
the	O
hand	O
or	O
foot	O
,	O
including	O
Dupuytren	other-disease
's	other-disease
contracture	other-disease
of	O
the	O
hand	O
.	O

On	O
December	O
9	O
,	O
Health	O
Canada	O
approved	O
the	O
tozinameran	O
COVID-19	other-disease
vaccine	O
developed	O
by	O
BioNTech	O
and	O
Pfizer	O
for	O
use	O
in	O
Canada	O
.	O

In	O
1986	O
,	O
the	O
hospital	O
was	O
at	O
the	O
center	O
of	O
a	O
criminal	O
case	O
after	O
a	O
GBI	other-disease
investigation	O
following	O
an	O
unusually	O
high	O
percentage	O
of	O
cardiac	O
arrests	O
.	O

With	O
the	O
first	O
episode	O
of	O
low	other-disease
back	other-disease
pain	other-disease
the	O
hope	O
is	O
a	O
complete	O
cure	O
;	O
however	O
,	O
if	O
the	O
problem	O
becomes	O
chronic	O
,	O
the	O
goals	O
may	O
change	O
to	O
pain	O
management	O
and	O
the	O
recovery	O
of	O
as	O
much	O
function	O
as	O
possible	O
.	O

Seven	O
cholera	other-disease
pandemics	other-disease
have	O
occurred	O
in	O
the	O
past	O
200	O
years	O
,	O
with	O
the	O
first	O
pandemic	other-disease
originating	other-disease
in	O
India	O
in	O
1817	O
.	O

Risk	O
factors	O
for	O
cardiomegaly	O
include	O
a	O
family	O
history	O
of	O
heart	other-disease
disease	other-disease
,	O
diabetes	other-disease
,	O
obesity	other-disease
,	O
hypertension	other-disease
,	O
history	O
of	O
alcohol	O
or	O
drug	O
abuse	O
,	O
the	O
lifestyle	O
that	O
consists	O
of	O
little	O
or	O
no	O
exercise	O
.	O

Candidiasis	other-disease
is	O
one	O
of	O
the	O
three	O
most	O
common	O
vaginal	O
infections	O
along	O
with	O
bacterial	other-disease
vaginosis	other-disease
and	O
trichomonas	other-disease
.	O

Other	O
inherited	O
causes	O
of	O
left	O
ventricular	O
hypertrophy	O
may	O
include	O
Fabry	other-disease
disease	O
,	O
Friedreich	other-disease
's	other-disease
ataxia	other-disease
,	O
and	O
certain	O
medications	O
such	O
as	O
tacrolimus	O
.	O

Germ	O
cell	O
tumor	O
(	O
GCT	other-disease
)	O
is	O
a	O
neoplasm	O
derived	O
from	O
germ	O
cells	O
.	O

Infection	O
with	O
Human	other-disease
Immunodeficiency	other-disease
Virus	other-disease
/	O
Acquired	other-disease
immunodeficiency	other-disease
Syndrome	other-disease
(	O
AIDS	other-disease
)	O
can	O
cause	O
a	O
related	O
salivary	O
gland	O
disease	O
known	O
as	O
Diffuse	other-disease
Infiltrative	other-disease
Lymphocytosis	other-disease
Syndrome	other-disease
(	O
DILS	other-disease
)	O
.	O

A	O
pseudocyst	other-disease
stage	O
has	O
been	O
recorded	O
and	O
may	O
be	O
the	O
form	O
taken	O
during	O
transmission	O
via	O
the	O
fecal-oral	O
route.7,8	O

Clomifene	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
malignant	O
melanomas	O
and	O
thyroid	other-disease
cancer	other-disease
.	O

In	O
severe	O
forms	O
,	O
botulism	other-disease
leads	O
to	O
paralysis	O
of	O
the	O
breathing	O
muscles	O
and	O
causes	O
respiratory	O
failure	O
.	O

The	O
presence	O
of	O
a	O
single	O
transverse	O
palmar	O
crease	O
can	O
be	O
,	O
but	O
is	O
not	O
always	O
,	O
a	O
symptom	O
associated	O
with	O
abnormal	O
medical	O
conditions	O
,	O
such	O
as	O
fetal	other-disease
alcohol	other-disease
syndrome	other-disease
,	O
or	O
with	O
genetic	other-disease
chromosomal	other-disease
abnormalities	other-disease
,	O
including	O
Down	other-disease
syndrome	other-disease
(	other-disease
chromosome	other-disease
21	other-disease
)	other-disease
,	O
cri	other-disease
du	other-disease
chat	other-disease
syndrome	other-disease
(	other-disease
chromosome	other-disease
5	other-disease
)	other-disease
,	O
Klinefelter	other-disease
syndrome	other-disease
,	O
Wolf-Hirschhorn	other-disease
Syndrome	other-disease
,	O
Noonan	other-disease
syndrome	other-disease
(	other-disease
chromosome	other-disease
12	other-disease
)	other-disease
,	O
Patau	other-disease
syndrome	other-disease
(	other-disease
chromosome	other-disease
13	other-disease
)	other-disease
,	O
IDIC	other-disease
15/Dup15q	other-disease
(	other-disease
chromosome	other-disease
15	other-disease
)	other-disease
,	O
Edward	other-disease
's	other-disease
syndrome	other-disease
(	other-disease
chromosome	other-disease
18	other-disease
)	other-disease
,	O
and	O
Aarskog-Scott	other-disease
syndrome	other-disease
(	other-disease
X-linked	other-disease
recessive	other-disease
)	other-disease
,	O
or	O
autosomal	other-disease
recessive	other-disease
disorder	other-disease
,	O
such	O
as	O
Leukocyte	other-disease
adhesion	other-disease
deficiency-2	other-disease
(	other-disease
LAD2	other-disease
)	other-disease
.	O

There	O
is	O
no	O
cure	O
for	O
Gerstmann	other-disease
syndrome	O
.	O

Radiation	O
therapy	O
appears	O
to	O
prolong	O
survival	O
in	O
people	O
with	O
resected	O
extrahepatic	other-disease
cholangiocarcinoma	other-disease
,	other-disease
and	O
the	O
few	O
reports	O
of	O
its	O
use	O
in	O
unresectable	O
cholangiocarcinoma	other-disease
appear	O
to	O
show	O
improved	O
survival	O
,	O
but	O
numbers	O
are	O
small	O
.	O

About	O
one	O
in	O
eight	O
Americans	O
(	O
as	O
of	O
2007	O
)	O
have	O
chronic	other-disease
kidney	other-disease
disease	other-disease
,	O
a	O
rate	O
that	O
is	O
increasing	O
over	O
time	O
.	O

Influenza	other-disease
B	other-disease
and	other-disease
C	other-disease
principally	O
infect	O
humans	O
,	O
minimizing	O
the	O
chance	O
that	O
a	O
reassortment	O
will	O
change	O
its	O
phenotype	O
drastically	O
.	O

Haemochromatosis	other-disease
arthropathy	O
includes	O
degenerative	O
osteoarthritis	other-disease
and	O
chondrocalcinosis	other-disease
.	O

The	O
potassium	other-disease
deficiency	other-disease
may	O
also	O
be	O
a	O
result	O
of	O
the	O
Chinese	O
diet	O
or	O
genetic	O
predisposition	O
.	O

The	O
studies	O
also	O
discovered	O
an	O
abnormally	O
high	O
rate	O
of	O
hypokalemia	other-disease
among	O
subjects	O
.	O

AIDS	other-disease
fears	O
and	O
homophobia	O
among	O
volunteers	O
in	O
an	O
AIDS	other-disease
prevention	O
program	O
.	O

infantile	other-disease
esotropia	other-disease
)	O
receive	O
strabismus	O
surgery	O
within	O
the	O
first	O
few	O
years	O
or	O
two	O
of	O
their	O
life	O
,	O
this	O
goes	O
along	O
with	O
the	O
hope	O
that	O
they	O
may	O
yet	O
develop	O
their	O
full	O
potential	O
for	O
binocular	O
vision	O
including	O
stereopsis	O
.	O

Unfortunately	O
,	O
the	O
kidneys	O
are	O
often	O
underdeveloped	O
resulting	O
in	O
a	O
30	O
%	O
death	O
rate	O
in	O
newborns	O
with	O
ARPKD	other-disease
.	O

Insomnia	other-disease
is	O
40	O
%	O
more	O
common	O
in	O
women	O
than	O
in	O
men	O
.	O

He	O
seek	O
to	O
improve	O
hypertension	other-disease
control	O
,	O
unhealthy	O
diets	O
and	O
physical	O
inactivity	O
on	O
a	O
national	O
and	O
global	O
scale	O
.	O

Such	O
a	O
method	O
has	O
been	O
applied	O
to	O
analyze	O
the	O
diffusion	O
of	O
endemic	O
diseases	O
such	O
as	O
the	other-disease
Dengue	other-disease
fever	other-disease
in	O
Colombia	O
,	O
as	O
well	O
as	O
the	O
diffusion	O
of	O
emergent	O
diseases	O
such	O
as	O
COVID-19	other-disease
in	O
Spain	O
and	O
Colombia	O
.	O

Compared	O
to	O
classic	O
PKU	other-disease
patients	O
,	O
patients	O
with	O
``	O
hyperphe	other-disease
``	O
have	O
greater	O
PAH	O
enzyme	O
activity	O
and	O
are	O
able	O
to	O
tolerate	O
larger	O
amounts	O
of	O
phenylalanine	O
in	O
their	O
diets	O
.	O

Former	O
What	O
Now	O
host	O
,	O
Virginie	O
Le	O
Brun	O
was	O
announced	O
to	O
have	O
been	O
cast	O
as	O
the	O
over	O
achieving	O
doctor	O
with	O
Aspergers	other-disease
.	O

The	O
term	O
blepharospasm	other-disease
[	O
'blef-a-ro-spaz-m	O
]	O
can	O
be	O
applied	O
to	O
any	O
abnormal	O
blinking	O
or	O
eyelid	O
tic	O
or	O
twitch	O
resulting	O
from	O
any	O
cause	O
,	O
ranging	O
from	O
dry	other-disease
eyes	other-disease
to	O
Tourette	other-disease
's	other-disease
syndrome	other-disease
to	O
tardive	other-disease
dyskinesia	other-disease
.	O

Rasmussen	other-disease
's	other-disease
aneurysm	other-disease
is	O
a	O
pulmonary	O
artery	O
aneurysm	O
associated	O
with	O
a	O
cavitary	O
lung	O
lesion	O
.	O

While	O
in	O
some	O
individuals	O
gingivitis	other-disease
never	O
progresses	O
to	O
periodontitis	other-disease
,	O
periodontitis	other-disease
is	O
always	O
preceded	O
by	O
gingivitis	other-disease
.	O

Erysipelas	other-disease
must	O
be	O
differentiated	O
from	O
h	O
erpes	other-disease
zoster	other-disease
,	O
angioedema	other-disease
,	O
contact	other-disease
dermatitis	other-disease
,	O
erythema	other-disease
chronicum	other-disease
migrans	other-disease
of	other-disease
early	other-disease
Lyme	other-disease
disease	other-disease
,	O
gout	other-disease
,	O
septic	other-disease
arthritis	other-disease
,	O
septic	other-disease
bursitis	other-disease
,	O
vasculitis	other-disease
,	O
allergic	other-disease
reaction	other-disease
to	O
an	O
insect	O
bite	O
,	O
acute	other-disease
drug	other-disease
reaction	other-disease
,	O
deep	other-disease
venous	other-disease
thrombosis	other-disease
and	O
diffuse	other-disease
inflammatory	other-disease
carcinoma	other-disease
of	other-disease
the	other-disease
breast	other-disease
.	O

Use	O
of	O
the	O
term	O
``	O
Da	other-disease
Costa	other-disease
's	other-disease
syndrome	other-disease
``	O
peaked	O
in	O
the	O
early	O
20th	O
century	O
.	O

The	O
molecule	O
is	O
highly	O
expressed	O
in	O
a	O
variety	O
of	O
cancer	O
cell	O
types	O
,	O
most	O
notably	O
breast	other-disease
cancer	other-disease
.	O

More	O
than	O
a	O
century	O
later	O
,	O
the	O
appearance	O
of	O
this	O
disease	O
in	O
young	O
gay	O
men	O
in	O
New	O
York	O
City	O
,	O
San	O
Francisco	O
and	O
other	O
coastal	O
cities	O
in	O
the	O
United	O
States	O
was	O
one	O
of	O
the	O
first	O
indications	O
that	O
a	O
new	O
disease	O
,	O
now	O
called	O
AIDS	other-disease
,	O
had	O
appeared	O
.	O

Both	O
HIT	other-disease
and	O
PNH	other-disease
require	O
particular	O
treatment	O
.	O

When	O
Giotto	O
died	O
on	O
8	O
January	O
1337	O
,	O
Andrea	O
Pisano	O
continued	O
the	O
building	O
until	O
work	O
was	O
halted	O
due	O
to	O
the	O
Black	other-disease
Death	other-disease
in	O
1348	O
.	O

Symptoms	O
of	O
mild	other-disease
hypothermia	other-disease
may	O
be	O
vague	O
,	O
with	O
sympathetic	O
nervous	O
system	O
excitation	O
(	O
shivering	O
,	O
high	O
blood	O
pressure	O
,	O
fast	O
heart	O
rate	O
,	O
fast	O
respiratory	O
rate	O
,	O
and	O
contraction	O
of	O
blood	O
vessels	O
)	O
.	O

Pemphigus	other-disease
foliaceus	other-disease
in	O
animals	O
produces	O
clusters	O
of	O
small	O
vesicles	O
that	O
quickly	O
evolve	O
into	O
pustules	O
.	O

Common	O
adverse	O
effects	O
in	O
studies	O
were	O
temporary	other-disease
bradycardia	other-disease
(	O
slow	other-disease
heartbeat	other-disease
)	O
,	O
usually	O
at	O
the	O
beginning	O
of	O
the	O
treatment	O
,	O
dyspnoea	other-disease
(	O
breathing	other-disease
difficulties	other-disease
)	O
,	O
and	O
increased	other-disease
liver	other-disease
enzymes	other-disease
(	O
without	O
symptoms	O
)	O
.	O

A	O
20th	O
anniversary	O
concert	O
event	O
was	O
held	O
in	O
May	O
1988	O
at	O
the	O
United	O
Nations	O
General	O
Assembly	O
to	O
benefit	O
children	O
with	O
AIDS	other-disease
.	O

Over	O
the	O
weekend	O
,	O
the	O
workers	O
lose	O
the	O
tolerance	O
,	O
and	O
when	O
they	O
are	O
re-exposed	O
on	O
Monday	O
,	O
the	O
drastic	O
vasodilation	O
produces	O
a	O
fast	O
heart	O
rate	O
,	O
dizziness	O
,	O
and	O
a	O
headache	O
,	O
this	O
is	O
referred	O
to	O
as	O
``	O
Monday	other-disease
disease	other-disease
.	O
''	O

For	O
example	O
,	O
Japan	O
has	O
no	O
mandatory	O
mumps	other-disease
vaccination	O
and	O
is	O
fourth	O
in	O
the	O
world	O
in	O
mumps	other-disease
cases	O
,	O
after	O
China	O
,	O
Nepal	O
and	O
Burkina	O
Faso	O
,	O
according	O
to	O
data	O
from	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
.	O

Several	O
clinical	O
trials	O
have	O
been	O
performed	O
to	O
assess	O
the	O
safety	O
and	O
effectivity	O
of	O
epigenetic	O
therapy	O
as	O
a	O
pretreatment	O
in	O
cancer	other-disease
therapy	O
.	O

Separation	other-disease
anxiety	other-disease
disorder	other-disease
(	O
SepAD	other-disease
)	O
is	O
the	O
feeling	O
of	O
excessive	O
and	O
inappropriate	O
levels	O
of	O
anxiety	O
over	O
being	O
separated	O
from	O
a	O
person	O
or	O
place	O
.	O

A	O
member	O
of	O
the	O
2017	O
National	O
Constituent	O
Assembly	O
and	O
the	O
Governor	O
of	O
the	O
Capital	O
District	O
,	O
Darío	O
Vivas	O
tested	O
positive	O
for	O
COVID-19	other-disease
on	O
19	O
July	O
.	O

A	O
recent	O
study	O
shows	O
that	O
Par6	O
associates	O
with	O
PKC-ι	O
but	O
not	O
with	O
PKC-zeta	O
in	O
melanoma	other-disease
.	O

This	O
change	O
causes	O
UWA-101	O
to	O
lack	O
cytotoxicity	O
and	O
MDMA	O
-like	O
behavioral	O
effects	O
in	O
animals	O
,	O
but	O
while	O
retaining	O
similar	O
or	O
slightly	O
improved	O
anti-	O
Parkinsonian	other-disease
effectiveness	O
when	O
compared	O
to	O
MDMA	O
.	O

Therefore	O
,	O
by	O
inhibiting	O
osteoclasts	O
,	O
it	O
prevents	O
osteoporosis	other-disease
.	O

People	O
with	O
Geschwind	other-disease
syndrome	other-disease
reported	O
higher	O
rates	O
of	O
atypical	O
or	O
altered	O
sexuality	O
.	O